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status (p = 0.026).  Conclusion: Cytoplasmic PHD2 expression 
has a strong impact on survival in gastric cancer patients. 
Therefore, PHD2 represents a useful predictive biomarker in 
the evaluation of high-risk patients. Furthermore, these re-
sults underline the importance of PHD2 in gastric carcino-
genesis and may identify PHD2 as a putative target for future 
gastric cancer therapy.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Despite a declining incidence over the past 20 years, 
gastric cancer still represents one of the most common 
cancer types in the Western world  [1–3] . According to re-
cent cancer statistics, gastric cancer is the fourth most 
common malignancy in the world and accounts for 10.4% 
of cancer deaths, which makes this entity the second 
leading cause of cancer-related deaths worldwide  [1–3] . 
 To date, the standard treatment for gastric cancer is 
surgery  [3–5] . Although there are many controversies 
about various aspects of surgical management, such as 
the extent of resection, the extent of lymphadenectomy or 
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 Abstract 
 Objective: According to recent research, prolyl hydroxylase 
domain 2 protein (PHD2) plays an important role in human 
carcinogenesis by inducing neovascularization and tumor 
growth. The aim of this study was to evaluate PHD2 expres-
sion patterns in primary gastric adenocarcinoma and to test 
for a potential predictive value of PHD2 expression in gastric 
cancer patients.  Methods: In a total of 121 patients, PHD2 
expression was investigated by immunohistochemistry in 
paraffin-embedded tissue and correlated with clinicopatho-
logical parameters and patient survival.  Results: 64 of 121 
gastric carcinomas (52.9%) showed PHD2 expression in tu-
mor cell cytoplasm. In univariate analysis, PHD2-negative pa-
tients had a significantly shortened survival in comparison 
with PHD2-postive patients (19.5 vs. 32.7 months, p = 0.02). 
Independent prognostic significance could be shown in 
multivariate analysis for PHD2 expression (p = 0.005), age at 
diagnosis (p = 0.012), lymph node status (p = 0.016) and R 
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the role of laparoscopic surgery  [3, 6, 7] , radical resection 
of the tumor remains the only curative treatment option 
for gastric cancer. However, since more than 50% of the 
patients receiving potentially curative resection relapse 
and a large number of patients present at an advanced 
stage of disease, systemic chemotherapy and radiothera-
py are also part of a multimodality treatment concept. 
Despite this, the prognosis of patients suffering from gas-
tric cancer is still poor, reaching 5-year survival rates of 
62% for patients with localized disease, but only 22% for 
patients with positive lymph nodes and 3% when the tu-
mor has spread to distant organ sites  [2] . Although many 
efforts are being made in order to improve the efficacy of 
chemotherapy, a considerable number of patients still 
display chemoresistance and usually die within 1 year 
due to tumor progression  [3] .
 Based on these facts, it becomes obvious that new 
therapeutic options are urgently needed in order to im-
prove patient survival. Furthermore, new predictive 
markers may be useful in the evaluation of high-risk pa-
tients.
 Evidence has accumulated showing that prolyl hy-
droxylase domain 2 protein [PHD2; alternative name for 
EGL nine homolog 1 (EGLN1)] plays an important role in 
the vascularization of solid tumors and carcinogenesis 
 [8] . Because of their rapid growth, most solid tumors ex-
hibit areas of hypoxia due to a high rate of cellular prolif-
eration and limited blood supply. Therefore, tumor cells 
must be able to adapt to hypoxia by inducing neovascu-
larization. Recent studies have shown that PHD2 repre-
sents one of the key oxygen sensors in this process  [9, 10] . 
In the presence of oxygen, PHD2 hydroxylates a subunit 
of hypoxia-inducible factor 1 (HIF1), which plays an im-
portant role in the development of a variety of cancers  [11, 
12] . After hydroxylation, HIF is able to interact with von 
Hippel-Lindau E3 ubiquitin ligase, a well-known tumor 
suppressor. This leads to the degradation of HIF and in-
hibits the transcription of proangiogenic factors. Con-
versely, in case of hypoxia, PHD2 remains inactive; as a 
consequence, HIF cannot interact with Hippel-Lindau 
E3 ubiquitin ligase and becomes transcriptionally active, 
resulting in the promotion of angiogenesis. Furthermore, 
HIF-mediated transcription also regulates many pro-
cesses in cellular homeostasis, including anaerobic me-
tabolism and oxygen-carrying capacity  [13, 14] .
 Although the role of PHD2 in tumorigenesis is still 
under discussion, several groups have recently shown 
that a shortage of PHD2 in tumor cells in vitro and in vivo 
leads to a dramatic enhancement of tumor growth  [15–
18] . Therefore, it appears that agents activating PHD2 in 
tumor cells may provide novel therapeutic options in 
cancer patients.
 The aim of the present study was to evaluate the cyto-
plasmic expression patterns of PHD2 in primary gastric 
adenocarcinoma. Furthermore, we investigated the link 
between PHD2 expression and clinicopathological data, 
including patient survival, in order to test for a potential 
predictive value of PHD2 expression in gastric carcinoma 
patients and to identify patients who might be suitable for 
novel target therapies.
 Methods 
 Between 1996 and 2002, a total of 121 consecutive patients who 
underwent complete or partial gastrectomy due to histologically 
confirmed gastric cancer at our center were enrolled in this study. 
The gastrectomy was performed according to the standard guide-
lines on the treatment of gastric cancer  [3] . Patients were excluded 
in case of presurgically treated cancer, recurrent gastric cancer or 
other malignancies. Furthermore, according to the guidelines, 
none of the patients received adjuvant or palliative chemotherapy 
after resection of the primary gastric carcinoma. Ninety-seven 
out of all patients had complete medical files until the end of the 
follow-up period and could therefore participate in the survival 
analysis. 
 Demographic and survival data of all patients were collected 
in a prospective database. Gastric cancer was histologically clas-
sified according to Lauren and staged according to the TNM 
guidelines (version 6). All patients in the study gave their written 
informed consent for the use of their tissues according to the Dec-
laration of Helsinki.
 Analysis of Cytoplasmic PHD2 Expression in Gastric Cancer 
Tissue 
 The cytoplasmic expression of PHD2 in tumor tissue was ana-
lyzed by immunohistochemistry. Formalin-fixed paraffin-em-
bedded tissue specimens were cut freshly (5   m). The sections 
were mounted on superfrost slides (Menzel Gläser, Braunschweig, 
Germany), dewaxed with xylene and gradually hydrated. Antigen 
retrieval was achieved by pressure cooking in 0.01  M citrate buffer 
for 5 min. Slides were incubated with an established polyclonal 
PHD2 anti-rabbit antibody (NB100–137; Novus Biologicals, Lit-
tleton, Colo., USA)  [19, 20] diluted 1: 4,000 in background reduc-
ing dilution buffer (Zymed, San Francisco, Calif., USA) at room 
temperature for 1 h. Detection took place according to the manu-
facturer’s instructions using a streptavidin-biotin system (Bio-
Genex, San Ramon, Calif., USA) with alkaline phosphatase as the 
reporting enzyme. Either diaminobenzidine chromogen (Dako, 
Germany) or Fast-red (Sigma-Aldrich, Munich, Germany) served 
as chromogen. Slides were then briefly counterstained with hema-
toxylin and mounted using Aquatex (Merck, Gernsheim, Germa-
ny). Omission of the primary antibody served as negative control.
 All tissue slides were evaluated independently by two expert 
pathologists of our center (A.S. and D.W.). To account for differ-
ences in staining, a semiquantitative immunoreactivity scoring 
system (IRS) was applied. To obtain the IRS, staining intensity 
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(0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = 
strong staining) as well as the percentage of cells stained (0 = no 
cells, 1 =  ! 10% of cells, 2 = 11–50% of cells, 3 = 51–80% of cells,
4 =  1 81% of cells) were evaluated for each patient and the respec-
tive scores were multiplied, resulting in an IRS range of 0–12. For 
statistical analysis, cases were grouped as either PHD2 positive 
(IRS 7–12) or PHD2 negative (IRS 0–6). The widely used IRS cut-
off value was defined prior to the evaluation of immunostaining 
and statistical data analysis  [21, 22] .
 Statistical Analysis 
 Statistical analysis was performed using SPSS 17.0 for Win-
dows (SPSS Inc., Chicago, Ill., USA) and the R (version 2.8.1, 
GNU/Linux) statistical software. All quantitative data were ex-
pressed as means and standard error of the mean (SEM), unless 
otherwise indicated. Fisher’s exact test and the   2 test were used 
for the assessment of a statistically significant correlation between 
PHD2 expression and clinicopathological parameters. Univariate 
survival analysis was performed according to Kaplan-Meier, sig-
nificant differences in survival curves were evaluated using the 
log-rank test. Multivariate survival analysis was undertaken with 
Cox’s regression model. A p value of less than 5% was regarded as 
statistically significant.
 Results 
 Demographics and Pathological Parameters 
 The study population consisted of 68 male (56.2%) and 
53 female (43.8%) patients who underwent gastric resec-
tion at our center for a histologically confirmed gastric 
cancer. Nearly 90% of the tumors were histologically clas-
sified as T2 or T3 and although more than 84% of the 
tumors showed lymphatic invasion, metastases could 
only be detected in 14 patients (11.6%). Detailed data on 
histological classification and staging of the tumors are 
summarized in  table 1 .
 Ninety-seven of these patients had complete medical 
files during the follow-up period and could therefore be 
included in the survival analysis. After a mean follow-up 
period of 18.3 months (SD 5.3 months), 31 of these pa-
tients (31.9%) were still alive reaching a mean overall sur-
vival of 28.6 months (SD 3.19 months). 
 Cytoplasmic PHD2 Expression in Gastric 
Adenocarcinoma and Correlation between PHD2 
Expression and Clinicopathological Parameters 
 In 64 of 121 gastric carcinomas (52.9%), immunohis-
tochemistry showed PHD2 expression in the tumor cell 
cytoplasm. Normal gastric mucosa displayed focal weak 
to moderate cytoplasmic immunostaining of the gastric 
glands. The surface epithelium was found to be PHD2 
negative ( fig. 1 ). A strong correlation was found between 
PHD2 expression and tumor growth pattern according to 
the Lauren classification, showing that intestinal tumors 
were more likely to express PHD2 than diffuse or mixed 
tumors (p = 0.001) ( fig. 2 ). No correlation existed between 
PHD2 expression and any other clinicopathological pa-
rameter listed in  table 1 . Nor could a link be established 
between PHD2 expression and tumor localization (p = 
0.076). 
 Impact of Cytoplasmic PHD2 Expression and 
Clinicopathological Parameters on Patient Survival 
 In univariate analysis, the following conventional 
prognostic factors had a statistically significant impact 
Table 1.  Overall cytoplasmic PHD2 expression and correlation to 
selected clinicopathological parameters in patients with gastric 
adenocarcinoma (Fisher’s exact test and 2 test)
Characteristics All 
cases 
PHD2 
negative
PHD2 
positive
p
value
All cases 121 57 (47.1%) 64 (52.9%)
Age at diagnosis
≤65 years 66 (54.5%) 35 (53.0%) 31 (47.0%) 0.201>65 years 55 (45.5%) 22 (40.0%) 33 (60.0%)
Tumor stage
T1 6 (5.0%) 4 (66.7%) 2 (33.3%)
0.718T2 52 (43.0%) 22 (42.3%) 30 (57.7%)T3 55 (45.5%) 26 (47.3.0%) 29 (52.7%)
T4 8 (6.6%) 5 (62.5%) 3 (37.5%)
Lymph node status
N0 25 (20.7%) 10 (71.0%) 15 (29.0%)
0.229N1 42 (34.7%) 18 (42.9%) 24 (57.1%)N2 39 (32.2%) 21 (53.8%) 18 (46.2%)
N3 15 (12.4%) 8 (53.3%) 7 (46.7%)
State of metastasis
M0 107 (88.4%) 48 (44.9%) 59 (55.1%) 0.255M1 14 (11.6%) 9 (64.3%) 5 (35.7%)
R status
R0 92 (76.0%) 42 (45.6%) 50 (54.6%) 0.670R1 29 (24.0%) 15 (51.7%) 14 (48.3%)
Lauren classfication
Intestinal 65 (53.7%) 21 (32.3%) 15 (31.9%)
0.001Diffuse 47 (38.8%) 32 (56.1%) 15 (31.9%)
Mixed 9 (7.4%) 4 (44.4%) 5 (55.6%)
Grade
G1 2 (1.7%) 2 (100.0%) 0 (00.0%)
0.167G2 27 (22.3%) 7 (25.9%) 20 (74.1%)
G3 92 (76.0%) 48 (52.2%) 44 (47.8%)
Tumor localization
Cardia 36 (29.8%) 16 (44.4%) 20 (55.6%)
0.076Corpus 43 (35.5%) 18 (41.9.9%) 25 (58.1%)Antrum 38 (31.4%) 23 (60.5%) 15 (39.5%)
Fundus 4 (3.3%) 0 (0.0%) 4 (100.0%)
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on patient survival: age at diagnosis (p = 0.036), tumor 
stage (p = 0.034), lymph node status (p = 0.021) and R sta-
tus (p = 0.016). Furthermore, we could establish a statisti-
cally significant influence of PHD2 expression on patient 
survival by log-rank testing (p = 0.020) ( table 2 ). PHD2-
negative patients had a significantly shorter survival 
compared with PHD2-positive patients (19.5 vs. 32.7 
months) ( fig. 3 ).
 Multivariate survival analysis (Cox regression model) 
including age at diagnosis, tumor stage, lymph node sta-
tus, R status and PHD2 expression did not reveal an in-
dependent statistically significant impact of tumor stage 
on patient survival (p = 0.230). In contrast, age at diagno-
sis (p = 0.012), lymph node status (p = 0.016) and R status 
(p = 0.026) as well as cytoplasmic PHD2 expression (p = 
0.005) showed independent prognostic significance, with 
PHD2 expression being the strongest predictive marker 
for patient survival ( table 3 ).
 Discussion 
 Due to wide variation in the prognosis of patients with 
gastric carcinomas, the evaluation of high-risk patients 
by reliable predictive markers has become more and more 
important in recent years. Conventional prognostic 
markers were investigated in several studies showing a 
high predictive value especially of histological parame-
ters like tumor stage and lymph node status  [3, 4] . These 
results are supported by the present study in which a 
strong predictive effect was found for tumor stage, nodal 
positivity as well as R status and age at diagnosis in uni-
variate analysis. In contrast, tumor localization and clas-
sification (according to Lauren) had no impact on patient 
survival.
Table 2.  Univariate survival analysis for cytoplasmic PHD2 ex-
pression and selected clinicopathological parameters
Cases Events Survival months log-rank
test 
(p value)mean SEM
Age at diagnosis
≤65 years 52 33 33.580 4.486 0.036>65 years 45 35 21.347 3.722
Tumor stage
T1 3 1 57.533 8.764
0.034T2 44 27 35.420 4.916T3 44 35 11.233 3.615
T4 6 5 11.233 4.320
Lymph node status
N0 19 12 37.714 7.228
0.021N1 36 24 30.425 4.647N2 29 22 18.654 3.179
N3 13 10 12.137 5.102
State of metastasis
M0 86 60 29.206 3.393 0.401M1 11 8 15.561 4.299
R status
R0 73 47 33.033 3.895 0.016R1 24 21 16.739 4.306
Lauren classification
Intestinal 52 34 32.768 4.540
0.634Diffuse 38 28 17.908 2.470
Mixed 7 6 26.419      10.588
Grade
G1 1 0 not
reached
not
reached 0.430G2 23 16 30.749 3.156
G3 73 52 25.438 3.178
Tumor localization
Cardia 28 19 30.949 5.789
0.343Corpus 35 23 29.314 4.963Antrum 31 23 24.108 4.502
Fundus 3 3 7.411 5.082
PHD2 expression
Negative 45 36 19.527 3.795 0.020Positive 52 32 32.733 4.048
p < 0.05 is considered as significant; significant p values are 
shown in bold.
 Fig. 1. PHD2 expression in normal gastric mucosa ( ! 20). Gastric 
glands beneath the surface epithelium focally display weak to 
moderate cytoplasmic PHD2 expression. Expression of PHD2 is 
absent in surface and foveolar epithelium. 
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 Since the identification of high-risk patients by reliable 
predictive markers is essential in the treatment of cancer 
patients, an increasing number of studies have recently 
focused on the expression of regulatory enzymes that 
play important roles in the development of cancer cells 
 [21, 22, ] . In addition to their usefulness as biomarkers, 
these enzymes may also be potential targets for novel 
therapies  [23] . In this context, several studies examined 
the expression patterns of PHD2, an oxygen sensor that 
controls cellular response to hypoxic stress by interacting 
with HIF1. In one of the first studies, Kato et al.  [16] 
showed that a high mutation rate of PHD2 with subse-
quent underexpression was associated with rapid tumor 
growth and a poor prognosis in patients with endome-
trial carcinomas. Similar results were presented by Lee et 
al.  [15]  in 2006. In a lineage of cell strains with varying 
transforming characteristics, PHD2 protein levels were 
inversely correlated with tumor-forming potential. An-
other study by Chan et al.  [17] hypothesizes that silencing 
of PHD2 might promote angiogenesis and tumor growth, 
which was investigated by comparing normal colonic tis-
sue and colon carcinoma tissue. The same study group 
also showed that silenced PHD2 in human colorectal 
cancer cell lines leads to tumor progression in vivo  [18] . 
The authors could not explain the fact that silencing of 
PHD2 did not affect tumor growth in vitro, but their ob-
servation suggests that the effect of PHD2 in human 
a b
c d
 Fig. 2. PHD2 expression in gastric adeno-
carcinoma tissue.  a ,  c Strong cytoplasmic 
expression of PHD2 was observed in intes-
tinal-type gastric carcinoma tissue ( a  ! 10, 
 c  ! 20).  b ,  d Weak or absent staining in 
diffuse-type carcinomas ( b  ! 10,  d  ! 20). 
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 Fig. 3. Kaplan-Meier curves depicting overall survival according 
to PHD2 expression patterns. 
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tumorigenesis is more complex and requires further 
studies. 
 To our knowledge, the present study is the first to 
evaluate the expression patterns of cytoplasmic PHD2 
in human gastric carcinoma. We demonstrated that loss 
of expression of PHD2 is strongly correlated with poor 
patient survival. In multivariate analysis, PHD2 turned 
out to be the strongest prognostic factor for patient sur-
vival which led to the conclusion that cytoplasmic PHD2 
expression may serve as a reliable prognostic immuno-
histochemical biomarker in gastric adenocarcinoma in 
the future.
 Besides the usefulness of the evaluation of cytoplasmic 
PHD2 expression in the identification of high-risk pa-
tients, our results might also lead to the development of 
novel drugs targeting PHD2 function. Although the ef-
fects of PHD2 on tumor growth are still under discussion 
and the observed statistical effects of PHD2 expression 
on prognosis do not necessarily imply functional rele-
vance, several studies revealed that drugs known to inter-
fere with PHD2 expression might become therapeutical-
ly valuable in the future, especially when combined with 
other antiangiogenesis drugs.
 Durczak et al.  [2] , for instance, showed that apicidin, a 
selective histone deacetylase 2 and 3 inhibitor, upregu-
lates PHD2 transcript levels in several cervical cancer cell 
lines. Another activator of PHD2 was found by Choi et al. 
 [25] . Activation of PHD2 by a new drug, KRH 102053, 
leads to a decrease in HIF1 levels in vitro, resulting in a 
downregulation of HIF-regulated downstream target 
genes, such as vascular endothelial growth factor and 
aldolase A. Although the upregulation of cytoplasmic 
PHD2 in tumor cells is hoped to lead to reduced tumor 
growth, animal models suitable to further study these 
important questions are still lacking. In a recently pub-
lished study, it could be demonstrated that an increase in 
PHD2 expression by an orally active endothelin B recep-
tor antagonist reduced tumor growth and neovascular-
ization in nude mice bearing melanoma xenografts  [26, 
27] . Since our data indicate an essential role of PHD2 in 
tumorigenesis of gastric cancer, these studies suggest that 
activation of PHD2 might represent a promising novel 
target therapy and might lead to a prolongation of sur-
vival in gastric cancer patients. Additionally, besides the 
effect of PHD2 on tumor growth, it could be shown by 
Brökers et al.  [28] that PHD2 inhibition in tumor cells 
may lead to increased chemoresistance. How this result 
can be used in the treatment of gastric cancer should also 
be an aspect of further research. 
 Elucidation of the bivalent role of PHD2 in tumor and 
endothelial cells represents another challenge. In con-
trast to the reports on PHD2 expression in tumor cells, 
Mazzone et al.  [29] reported that inhibition of PHD2 in 
endothelial cells leads to normalization of the endothe-
lial barrier, resulting in improved tumor oxygenation and 
prolonged survival. They showed that in PHD2-haplode-
ficient mice, reduced endothelial PHD2 expression did 
not affect tumor growth but prevented metastases by sta-
bilization of tumor vessels. With respect to future tumor 
therapies, the question whether selective inhibition of en-
dothelial PHD2 can be combined with activation of tu-
mor cell PHD2 remains challenging.
 Conclusions 
 In conclusion, we present the first study showing that 
cytoplasmic PHD2 is a strong prognostic biomarker for 
gastric adenocarcinoma that might be useful in identify-
ing high-risk patients. Since PHD2 plays an important 
role in tumorigenesis, PHD2 might represent a potential 
target for chemotherapy in gastric cancer patients in the 
future. However, there is an urgent need of further stud-
ies in order to improve our understanding of the role of 
PHD2 in gastric carcinogenesis and to evaluate possible 
therapeutic options evolving from these findings.
 
Table 3.  Multivariate survival analysis for PHD2 expression and 
selected clinicopathological parameters using the Cox regression 
model
O verall survival
HR 95% CI p value
Age at diagnosis 0.012
≤65 years 0.532 0.325–0.871
>65 years referent
Lymph node status 0.016
N0 0.255 0.105–0.621
N1 0.336 0.156–0.725
N2 0.402 0.181–0.895
N3 referent
R status 0.026
R0 0.547 0.322–0.930
R1 referent
PHD2-expression 0.005
Negative 2.070 1.247–3.439
Positive referent
Not significant
Tumor stage 0.230
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